Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information In progress
Process Cost Comparison Standard
ID number 6289

Provisional Schedule

Expected publication 04 December 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Stakeholders

Companies sponsors Pfizer (crizotinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Oncogene Cancer Research
  Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Roche (entrectinib) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
31 October 2024 - 14 November 2024 Final draft guidance
17 April 2024 Invitation to participate
08 December 2023 - 12 January 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
07 November 2023 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual